• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation W

tetano

Editor, Senior Moderator
Front Immunol


. 2022 Jan 12;12:803647.
doi: 10.3389/fimmu.2021.803647. eCollection 2021.
Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants


Akitsu Masuda[SUP] 1 [/SUP], Jae Man Lee[SUP] 2 [/SUP], Takeshi Miyata[SUP] 3 [/SUP], Hiroaki Mon[SUP] 1 [/SUP], Keita Sato[SUP] 3 [/SUP], Kosuke Oyama[SUP] 4 [/SUP], Yasuteru Sakurai[SUP] 5 6 [/SUP], Jiro Yasuda[SUP] 5 6 [/SUP], Daisuke Takahashi[SUP] 4 [/SUP], Tadashi Ueda[SUP] 4 [/SUP], Yuri Kato[SUP] 7 [/SUP], Motohiro Nishida[SUP] 7 [/SUP], Noriko Karasaki[SUP] 1 [/SUP], Kohei Kakino[SUP] 1 [/SUP], Takeru Ebihara[SUP] 1 [/SUP], Takumi Nagasato[SUP] 1 [/SUP], Masato Hino[SUP] 8 [/SUP], Ayaka Nakashima[SUP] 9 [/SUP], Kengo Suzuki[SUP] 9 [/SUP], Yoshino Tonooka[SUP] 1 [/SUP], Miyu Tanaka[SUP] 1 [/SUP], Takato Moriyama[SUP] 1 [/SUP], Hirokazu Nakatake[SUP] 10 [/SUP], Ryosuke Fujita[SUP] 8 [/SUP], Takahiro Kusakabe[SUP] 1 [/SUP]



Affiliations

Abstract

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a spread of coronavirus disease 2019 (COVID-19) globally. In order to end the COVID-19 pandemic, an effective vaccine against SARS-CoV-2 must be produced at low cost and disseminated worldwide. The spike (S) protein of coronaviruses plays a pivotal role in the infection to host cells. Therefore, targeting the S protein is one of the most rational approaches in developing vaccines and therapeutic agents. In this study, we optimized the expression of secreted trimerized S protein of SARS-CoV-2 using a silkworm-baculovirus expression vector system and evaluated its immunogenicity in mice. The results showed that the S protein forming the trimeric structure was the most stable when the chicken cartilage matrix protein was used as the trimeric motif and could be purified in large amounts from the serum of silkworm larvae. The purified S protein efficiently induced antigen-specific antibodies in mouse serum without adjuvant, but its ability to induce neutralizing antibodies was low. After examining several adjuvants, the use of Alum adjuvant was the most effective in inducing strong neutralizing antibody induction. We also examined the adjuvant effect of paramylon from Euglena gracilis when administered with the S protein. Our results highlight the effectiveness and suitable construct design of the S protein produced in silkworms for the subunit vaccine development against SARS-CoV-2.

Keywords: Alum; COVID-19; SARS-CoV-2; adjuvant; paramylon; silkworm-baculovirus expression vector system; spike (S) protein.
 
Back
Top Bottom